It's a really good question. I think it's something that folks in the insulin space have been grappling with quite a lot—trying to understand why this is going on, what the factors are, and where we can have an impact to see some relief.
There are a couple of issues going on here. The first is that globally, as you heard me mention, one in two people cannot access insulin. There are several different reasons for this, and only one of them is that the market is dominated by these three big companies. There are concerns about tariffs and concerns about physical access to the drug in different communities.
The second big issue going on in insulin is the price that's going up and up and up. We're seeing this really hit hard in the United States in particular right now. We've looked at emerging smaller companies that are trying to enter the insulin space. We think what's happening is that they're being bought by these big three insulin manufacturers. They're the subject of lawsuits for anti-competitive behaviour and a whole host of other things from different states in the United States right now—but I don't know; I wish there was a better answer, and I wish there was a pharmaceutical company that had a good heart.